- Home
- AGEN vs FBLG Comparison
AGEN vs FBLG Comparison
Compare AGEN & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FBLG
- Stock Information
- Founded
- AGEN 1994
- FBLG 2021
- Country
- AGEN United States
- FBLG United States
- Employees
- AGEN N/A
- FBLG N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FBLG
- Sector
- AGEN Health Care
- FBLG
- Exchange
- AGEN Nasdaq
- FBLG NYSE
- Market Cap
- AGEN 38.1M
- FBLG 37.1M
- IPO Year
- AGEN 2000
- FBLG 2024
- Fundamental
- Price
- AGEN $2.96
- FBLG $1.27
- Analyst Decision
- AGEN Buy
- FBLG Strong Buy
- Analyst Count
- AGEN 4
- FBLG 4
- Target Price
- AGEN $8.00
- FBLG $13.00
- AVG Volume (30 Days)
- AGEN 655.0K
- FBLG 221.4K
- Earning Date
- AGEN 05-06-2025
- FBLG 05-13-2025
- Dividend Yield
- AGEN N/A
- FBLG N/A
- EPS Growth
- AGEN N/A
- FBLG N/A
- EPS
- AGEN N/A
- FBLG N/A
- Revenue
- AGEN $103,463,000.00
- FBLG N/A
- Revenue This Year
- AGEN $4.03
- FBLG N/A
- Revenue Next Year
- AGEN $5.57
- FBLG N/A
- P/E Ratio
- AGEN N/A
- FBLG N/A
- Revenue Growth
- AGEN N/A
- FBLG N/A
- 52 Week Low
- AGEN $1.38
- FBLG $0.76
- 52 Week High
- AGEN $19.69
- FBLG $13.59
- Technical
- Relative Strength Index (RSI)
- AGEN 78.44
- FBLG 60.94
- Support Level
- AGEN $1.60
- FBLG $0.76
- Resistance Level
- AGEN $1.83
- FBLG $0.87
- Average True Range (ATR)
- AGEN 0.31
- FBLG 0.14
- MACD
- AGEN 0.21
- FBLG 0.06
- Stochastic Oscillator
- AGEN 97.52
- FBLG 64.80
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.